Inmune Bio Stock Today

INMB Stock  USD 5.44  0.28  4.90%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 27

 
High
 
Low
Below Average
INmune Bio is trading at 5.44 as of the 14th of November 2024, a 4.9 percent decrease since the beginning of the trading day. The stock's open price was 5.72. INmune Bio has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for INmune Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of October 2024 and ending today, the 14th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of February 2019
Category
Healthcare
Classification
Health Care
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 22.17 M outstanding shares of which 3.48 M shares are currently shorted by private and institutional investors with about 14.05 trading days to cover. More on INmune Bio

Moving together with INmune Stock

  0.74VALN Valneva SE ADRPairCorr

Moving against INmune Stock

  0.74DOMH Dominari HoldingsPairCorr
  0.67DMAC DiaMedica TherapeuticsPairCorr
  0.58DNLI Denali TherapeuticsPairCorr
  0.32DSGN Design TherapeuticsPairCorr

INmune Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00260.0027
Notably Down
Slightly volatile
Total Current Liabilities19.4 M18.5 M
Sufficiently Up
Slightly volatile
Total Assets41.6 M57 M
Way Down
Slightly volatile
Total Current Assets27.2 M39.9 M
Way Down
Slightly volatile
Debt Levels
INmune Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand INmune Bio's financial leverage. It provides some insight into what part of INmune Bio's total assets is financed by creditors.
Liquidity
INmune Bio currently holds 10.44 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. INmune Bio has a current ratio of 30.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about INmune Bio's use of debt, we should always consider it together with its cash and equity.

Sale Purchase Of Stock

32,775
INmune Bio (INMB) is traded on NASDAQ Exchange in USA. It is located in 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432 and employs 11 people. INmune Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 126.83 M. INmune Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 22.17 M outstanding shares of which 3.48 M shares are currently shorted by private and institutional investors with about 14.05 trading days to cover. INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41.
Check INmune Bio Probability Of Bankruptcy
Ownership Allocation
INmune Bio has a total of 22.17 Million outstanding shares. INmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check INmune Ownership Details

INmune Stock Institutional Holders

InstituionRecorded OnShares
Millennium Management Llc2024-06-30
92.7 K
Royal Bank Of Canada2024-06-30
62.6 K
Bank Of New York Mellon Corp2024-06-30
58.6 K
Morgan Stanley - Brokerage Accounts2024-06-30
56.8 K
Westside Investment Management, Inc.2024-06-30
45.3 K
Susquehanna International Group, Llp2024-06-30
42.8 K
Fermata Advisors, Llc2024-09-30
42.7 K
Ubs Group Ag2024-06-30
40.3 K
Charles Schwab Investment Management Inc2024-06-30
37.3 K
Blackrock Inc2024-06-30
812.9 K
Vanguard Group Inc2024-06-30
628.3 K
View INmune Bio Diagnostics

INmune Bio Historical Income Statement

At present, INmune Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 21.3 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M. View More Fundamentals

INmune Stock Against Markets

INmune Bio Corporate Management

Christopher BarnumHead NeuroscienceProfile
BSc FRCPathChief OfficerProfile
Raymond MDPresident, CoFounderProfile
Joshua EsqGeneral CounselProfile
David MBATreasurer CFOProfile
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
0.002
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.45)
Return On Equity
(0.99)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.